Bioctogen Boston Corporation is a Biotech CRO offering Immuno-Oncology drug validation services that rely on independently-developed humanized immune-checkpoint mouse models (e.g. B-hPD-1 mice) and immune-deficient, human immune system-reconstituted mice (B-NDG model). Biocytogen also offers antibody humanized mouse models, CDX models, PDX models, in vivo services, PK/PD services, ect. All models are generated by our custom gene targeting platform, featuring CRISPR-based EGE® technology, which increases large fragment knockin efficiency by 10-20-fold. Learn more at www.biocytogen.com.
Myriad RBM, Inc. is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.